Vicuron Extends Pfizer Deal to Develop Oral Antibiotics

Vicuron Pharmaceuticals Inc. said Wednesday after the closing bell that its collaboration with Pfizer Inc. has been extended for another year. The collaboration was established to develop next- generation oxazolidinones, the first new class of antibiotics in more than 30 years, King of Prussia, Pa.-based Vicuron said. Financial terms of the deal were not disclosed.

Interactive Investor (http://www.iii.co.uk/shares/?type=news&articleid=5251886&action=article)